Rutin stabilizes a non-nucleating tau conformer through direct MAPT repeat-domain binding

Hypothesis 1: Rutin suppresses tau aggregation by binding exposed beta-sheet nucleation motifs in MAPT repeat domains, especially PHF6-like steric zipper surfaces, and stabilizing a less aggregation-prone monomer ensemble. The flavonol core could provide pi-stacking against aromatic residues while the glycoside hydroxyl network reduces dehydration at early oligomer interfaces. Test: recombinant K18/K19 tau seeding, HDX-MS footprinting, and cryo-EM of fibrils assembled with rutin.

Hypothesis 2: Rutin acts upstream of aggregation by chelating redox-active metals and dampening oxidative cross-li

Hypothesis 1 is plausible but vulnerable to the classic polyphenol problem: apparent anti-aggregation effects can reflect colloidal interference, fluorescence-quenching artifacts, or non-specific binding to protein surfaces. If rutin only works at high micromolar concentrations in thioflavin assays, the mechanistic claim is too strong without orthogonal biophysics.

Hypothesis 2 explains indirect benefit but not specificity for tau oligomer structure. Many antioxidants reduce oxidative stress without meaningfully changing the conformational ensemble that drives templated tau seeding. The falsi

From a drug-discovery perspective, the strongest near-term program is to separate direct tau-binding from systems-level proteostasis effects. Use recombinant aggregation and seeding assays first, then repeat the best conditions in human iPSC neurons expressing seeded tau to determine whether the mechanism scales from purified protein to disease-relevant biology.

Rutin's liabilities are familiar: limited oral bioavailability, uncertain CNS exposure, and promiscuous chemistry typical of polyphenols. That does not kill the program, but it shifts the emphasis toward analog design, formulation, or

{"ranked_hypotheses": [{"title": "Rutin stabilizes a non-nucleating tau conformer through direct MAPT repeat-domain binding", "description": "Rutin engages exposed tau aggregation motifs and lowers early oligomer nucleation, with strongest support expected from cell-free seeding and structural footprinting assays.", "target_gene": "MAPT", "dimension_scores": {"evidence_strength": 0.55, "novelty": 0.72, "feasibility": 0.69, "therapeutic_potential": 0.63, "mechanistic_plausibility": 0.71, "druggability": 0.46, "safety_profile": 0.69, "competitive_landscape": 0.58, "data_availability": 0.67, "rep